Nektar Therapeutics reported $13.09M in Interest Expense on Debt for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
ALKERMES ALKS:US 2.41M 537K
Amgen AMGN:US $ 281M 4M
Baxter International BAX:US $ 37M 0M
Biocryst Pharmaceuticals BCRX:US $ 13.5M 0.59M
Biogen BIIB:US $ 66.3M 9.9M
Bristol Myers Squibb BMY:US $ 330M 23M
Eli Lilly And LLY:US $ 86.9M 0.9M
Esperion Therapeutics ESPR:US $ 11.14M 3.02M
Gilead Sciences GILD:US $ 256M 1M
Halozyme Therapeutics HALO:US $ 1.75M 0.21M
Immunogen IMGN:US $ 3.58M 1.09M
IONIS PHARMACEUT IONS:US $ 2.36M 0.06M
Ironwood Pharmaceuticals IRWD:US $ 7.73M 0.11M
Karyopharm Therapeutics KPTI:US $ 5M 94K
Nektar Therapeutics NKTR:US $ 13.09M 0.21M
Neurocrine Biosciences NBIX:US $ 6.2M 0.2M
Novartis NOVN:VX 201M 1000K
Pfizer PFE:US $ 316M 20M
Sarepta Therapeutics SRPT:US $ 15.83M 0.18M
Teva Pharmaceutical TEVA:IT 240M 1000K
YTE INCY:US $ 0.36M 0M